Surrozen Collaborates with Boehringer Ingelheim to Develop SZN-413 for Retinal Disease
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 21 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2738 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its pipeline in diabetic retinopathy, Boehringer Ingelheim has entered into a licensing agreement with Surrozen in a deal worth up to US$599 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS